Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction
These real-world findings indicate that patients with CrCl <30 ml/min experienced outcomes comparable to those with higher renal function, providing important evidence in a population that is often excluded from clinical trials.
Authors
- Ryan D. Chow (ORCID: https://orcid.org/0000-0002-1872-6307)
- Ronac Mamtani (ORCID: https://orcid.org/0000-0002-8267-5356)
- Henry K. Litt (ORCID: https://orcid.org/0000-0002-3158-8797)
Institutions
- Penn Center for AIDS Research (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1016/j.urolonc.2025.10.016
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01